AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8594657 — intervention group
Group type: COMPARATOR
Intervention: Sodium aurothiomalate or D-penicillamine (group-B)
Number of subjects: 157
Study 1971165 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (180 mg)
Number of subjects: 12
Study 7369913 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cefaclor
Number of subjects: 39
Study 7369913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefaclor
Number of subjects: 39
Study 29952733 — intervention group
Group type: EXPERIMENTAL
Intervention: New ergonomic seat prototype
Number of subjects: 20
Study 29952733 — intervention group
Group type: COMPARATOR
Intervention: Industrial standard seat
Number of subjects: 20
Study 27399595 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-PTSD
Number of subjects: 0
Study 25795376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty including cutting and repositioning of the depressor septi nasi muscle
Number of subjects: 80
Study 25795376 — intervention group
Group type: COMPARATOR
Intervention: Rhinoplasty without manipulation of the depressor septi nasi muscle (control)
Number of subjects: 80
Study 23252444 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 321
Study 23252444 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency physical therapy
Number of subjects: 321
Study 23252444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study 21497001 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial wound closure (group I)
Number of subjects: 82
Study 21497001 — intervention group
Group type: COMPARATOR
Intervention: Total wound closure (group II)
Number of subjects: 82
Study 19539473 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification system for delirium subtypes using a commercial accelerometer-based activity monitor
Number of subjects: 40
Study 19539473 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification trees based on periods of sitting/lying, standing, stepping, and number of postural transitions
Number of subjects: 40
Study 19539473 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed ward behavior
Number of subjects: 40
Study 17476469 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended hemodynamic monitoring with anesthesiologists aware of CI results
Number of subjects: 28
Study 17476469 — intervention group
Group type: COMPARATOR
Intervention: Routine hemodynamic monitoring with anesthesiologists blinded to CI results
Number of subjects: 28
Study 14701778 — intervention group
Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (MGd) 5 mg/kg/d with whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions
Number of subjects: 401
Study 14701778 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions without motexafin gadolinium (MGd)
Number of subjects: 401
Study 11530563 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 20
Study 11530563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9180238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modulating therapy that lowers LDL cholesterol
Number of subjects: 0
Study 9180238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modulating therapy that lowers LDL cholesterol and decreases serum triglyceride and/or increases HDL cholesterol
Number of subjects: 0
Study 8506881 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group education
Number of subjects: 323
Study 8506881 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education
Number of subjects: 323
Study 8506881 — intervention group
Group type: COMPARATOR
Intervention: Usual control (no formal asthma education)
Number of subjects: 323
Study 8506881 — intervention group
Group type: COMPARATOR
Intervention: Information (workbook) control
Number of subjects: 323
Study 3325929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 56
Study 3325929 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole plus colistin
Number of subjects: 56
Study 3325929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 56
Study 3325929 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 56
Study 30354767 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27999883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg in pediatric subjects
Number of subjects: 0
Study 27999883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg in pediatric subjects
Number of subjects: 0
Study 27999883 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin 25 mg in adults
Number of subjects: 0
Study 27999883 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 0
Study 26465928 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental decision support alert for critically low systolic blood pressure (SBP)
Number of subjects: 3165
Study 26465928 — intervention group
Group type: COMPARATOR
Intervention: Routine management (no alerts)
Number of subjects: 3165
Study 23260415 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 45
Study 23260415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22030233 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide, 40mg
Number of subjects: 79
Study 22030233 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide, 20mg
Number of subjects: 79
Study 22030233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 22030233 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide, 40mg and 20mg
Number of subjects: 79
Study 18463518 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVTA
Number of subjects: 28
Study 18463518 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg IVTA
Number of subjects: 28
Study 16571278 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Huangqi Guizhi Wuwu Decoction (JHGWD) combined with chemotherapy and oxaliplatin
Number of subjects: 31
Study 16571278 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 31
Study 12928469 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials funded by nonprofit organizations
Number of subjects: 370
Study 12928469 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials not reporting funding
Number of subjects: 370
Study 12928469 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials funded by both nonprofit and for-profit organizations
Number of subjects: 370
Study 12928469 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials funded by for-profit organizations
Number of subjects: 370
Study 11144398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg daily (QD)
Number of subjects: 384
Study 11144398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg twice a day (BID)
Number of subjects: 384
Study 11144398 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 40/10 mg/kg/day divided TID
Number of subjects: 384
Study 11144398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg BID
Number of subjects: 384
Study 11144398 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 384
Study 9225366 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human Interleukin‐3 (rhIL‐3) at doses of 0.5, 1.0, 5.0, 7.5, and 10 micrograms/kg
Number of subjects: 30
Study 9225366 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human Interleukin‐3 (rhIL‐3) at 10 micrograms/kg
Number of subjects: 30
Study 9225366 — intervention group
Group type: COMPARATOR
Intervention: Control cycles (no cytokine therapy)
Number of subjects: 30
Study 9225366 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human Granulocyte‐Macrophage Colony‐Stimulating Factor (rhGM‐CSF) at 3.0 micrograms/kg
Number of subjects: 30
Study 9225366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine treatment (rhIL‐3 and rhGM‐CSF)
Number of subjects: 30
Study 8452175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg once a day)
Number of subjects: 316
Study 8452175 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (0.5‐2 g three times a day or 1‐2 g twice a day)
Number of subjects: 316
Study 3732047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy in initial treatment
Number of subjects: 0
Study 3732047 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 31144852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 20
Study 31144852 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 20
Study 31144852 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist behaviors in early sessions
Number of subjects: 20
Study 31144852 — intervention group
Group type: EXPERIMENTAL
Intervention: PQS prototypes
Number of subjects: 20
Study 28056021 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX 200mg/d for 4 weeks (DOX 4w)
Number of subjects: 158
Study 28056021 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX 200mg/d for 3 weeks plus ALB 800mg/d for 3 days (DOX 3w + ALB 3d)
Number of subjects: 158
Study 28056021 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN 200mg/d for 3 weeks (MIN 3w)
Number of subjects: 158
Study 28056021 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX 200mg/d for 3 weeks (DOX 3w)
Number of subjects: 158
Study 28056021 — intervention group
Group type: COMPARATOR
Intervention: ALB 800mg for 3 days (ALB 3d)
Number of subjects: 158
Study 25885678 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal verbal report
Number of subjects: 0
Study 25885678 — intervention group
Group type: EXPERIMENTAL
Intervention: Unused returned medication
Number of subjects: 0
Study 25885678 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nevirapine concentration >100 ng/ml
Number of subjects: 0
Study 25885678 — intervention group
Group type: COMPARATOR
Intervention: Maternal verbal reports
Number of subjects: 0
Study 25885678 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed doses by maternal verbal reports
Number of subjects: 0
Study 23449923 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 707
Study 23449923 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 707
Study 20809267 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched chicken (4 portions of 200 g/week)
Number of subjects: 24
Study 20809267 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched chicken (4 portions of 200 g/week)
Number of subjects: 24
Study 17717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfurous mineral water (500 ml day(‐1) for 2 weeks)
Number of subjects: 40
Study 17717532 — intervention group
Group type: COMPARATOR
Intervention: Control (without sulfurous mineral water)
Number of subjects: 40
Study 17353434 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive evaluation using 64‐slice multislice computed tomography
Number of subjects: 105
Study 17353434 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe mitral regurgitation
Number of subjects: 105
Study 15569141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care using Asian link workers and extra community diabetes specialist nurse sessions
Number of subjects: 361
Study 15569141 — intervention group
Group type: COMPARATOR
Intervention: Standard practice care
Number of subjects: 361
Study 11419888 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus plus 12-h infusion
Number of subjects: 9290
Study 11419888 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 9290
Study 9405748 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic intervention for removal of gallstones and reestablishment of biliary drainage
Number of subjects: 800
Study 8728734 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with 30% PIMax
Number of subjects: 20
Study 8728734 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with 10% PIMax
Number of subjects: 20
Study 8728734 — intervention group
Group type: COMPARATOR
Intervention: Crossover after 10 weeks
Number of subjects: 20
Study 2600754 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 72
Study 2600754 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 72
Study 2600754 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 973673 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy
Number of subjects: 44
Study 973673 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy
Number of subjects: 44
Study 31915189 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 15
Study 31915189 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight sleep loss
Number of subjects: 15
Study 30196572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent (SES)
Number of subjects: 148
Study 30196572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS)
Number of subjects: 148
Study 30196572 — intervention group
Group type: COMPARATOR
Intervention: Control group (SES)
Number of subjects: 148
Study 30196572 — intervention group
Group type: COMPARATOR
Intervention: Control group (BRS)
Number of subjects: 148
Study 28515160 — intervention group
Group type: EXPERIMENTAL
Intervention: Epro and UFA condition
Number of subjects: 25
Study 28515160 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate condition
Number of subjects: 25
Study 26200146 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX solution for 60 s after acid etching and before adhesive application
Number of subjects: 42
Study 26200146 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 42
Study 23637033 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle group (received a second bolus of 20 mL of 0.2% ropivacaine postoperatively)
Number of subjects: 30
Study 23637033 — intervention group
Group type: COMPARATOR
Intervention: Single-shot group (received 25-30 mL of 1.5% lidocaine and 0.125% bupivacaine)
Number of subjects: 30
Study 23637033 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle group
Number of subjects: 30
Study 23637033 — intervention group
Group type: COMPARATOR
Intervention: Single-shot group
Number of subjects: 30
Study 21269402 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone pellets (75 mg each, 8 to 12 pellets, total 450 mg to 900 mg)
Number of subjects: 0
Study 18563471 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4-6 mg/d)
Number of subjects: 33
Study 18563471 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (20-50 mg/d)
Number of subjects: 33
Study 17586417 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 4278
Study 17586417 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 4278
Study 17586417 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 4278
Study 17586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/HCTZ 12.5 mg
Number of subjects: 4278
Study 17586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/HCTZ 12.5 mg
Number of subjects: 4278
Study 17586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/HCTZ (stage 2 hypertension)
Number of subjects: 4278
Study 17586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/HCTZ (stage 2 hypertension)
Number of subjects: 4278
Study 17586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/HCTZ (stage 1 hypertension)
Number of subjects: 4278
Study 17586417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4278
Study 15556954 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 1287
Study 15556954 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise classes
Number of subjects: 1287
Study 15556954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (manipulation followed by exercise)
Number of subjects: 1287
Study 15556954 — intervention group
Group type: COMPARATOR
Intervention: Best care
Number of subjects: 1287
Study 11162286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with indomethacin
Number of subjects: 0
Study 11162286 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 0
Study 11162286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9158189 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m-sestamibi scintigraphy (MIBI scintigraphy)
Number of subjects: 36
Study 9158189 — intervention group
Group type: COMPARATOR
Intervention: Physical and histological examination
Number of subjects: 36
Study 7900078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 IU
Number of subjects: 0
Study 7900078 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 0
Study 7900078 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg body weight (mean 75 mg)
Number of subjects: 0
Study 7900078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 7900078 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (high dose)
Number of subjects: 0
Study 7900078 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess platelet factor 4 (PF4)
Number of subjects: 0
Study 2839439 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Platinum (DDP) Etoposide (VP‐16) chemotherapy and twice‐daily, 150 cGy radiotherapy to a total dose of 4500 cGy in 3 weeks.
Number of subjects: 23
Study 31701163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 67
Study 31701163 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 67
Study 25116293 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 24
Study 25116293 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 24
Study 25116293 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SHAM)
Number of subjects: 24
Study 23168166 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stretch force method for assessing flexibility
Number of subjects: 10
Study 21974760 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ 160/12.5 mg, titrated to 320/25 mg at week 4
Number of subjects: 401
Study 21974760 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/HCTZ (HCTZ 12.5 mg monotherapy, then amlodipine 5 mg at week 8 and 10 mg at week 12)
Number of subjects: 401
Study 21974760 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 401
Study 21974760 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/HCTZ
Number of subjects: 401
Study 18381905 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXB-A (higher dose)
Number of subjects: 31
Study 18381905 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXB-A (lower dose)
Number of subjects: 31
Study 18381905 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXB-A (first treatment arm)
Number of subjects: 31
Study 18381905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17532523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01 mg/kg
Number of subjects: 35
Study 17532523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.02 mg/kg
Number of subjects: 35
Study 17532523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 14764932 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS) and contrast‐enhanced MR angiography (CEMRA)
Number of subjects: 150
Study 14764932 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS) and CT angiography (CTA)
Number of subjects: 150
Study 14764932 — intervention group
Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 150
Study 14764932 — intervention group
Group type: COMPARATOR
Intervention: Contrast‐enhanced MR angiography (CEMRA)
Number of subjects: 150
Study 14764932 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound (DUS)
Number of subjects: 150
Study 11324378 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dementia
Number of subjects: 0
Study 11324378 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 0
Study 11324378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ageing
Number of subjects: 0
Study 9450162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (300 mg, Orfiril long) after fasting
Number of subjects: 16
Study 9450162 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (300 mg, Orfiril long) after a high energy high fat breakfast
Number of subjects: 16
Study 8192698 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg sustained-release theophylline (Bronchoretard) administered in a fasting state
Number of subjects: 18
Study 8192698 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg sustained-release theophylline (Bronchoretard) administered after a standard meal
Number of subjects: 18
Study 8192698 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg sustained-release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Number of subjects: 18
Study 8192698 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of food with theophylline
Number of subjects: 18
Study 3310776 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1
Study 3310776 — intervention group
Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 1
Study 30306604 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg l-selenomethionine daily for 6 months
Number of subjects: 71
Study 30306604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71